Bausch Health: an ex-sinner to buy now
Pharmaceutical firm Bausch Health, formerly known as Valeant, is putting a dodgy past behind it.
Three laggards to buy for long-term growth
Some of the best long-term capital-growth opportunities lie in companies that have struggled over the past few years, says professional investor Ben R…
The smart money is backing print – so why is Pearson flogging The Economist?
In selling The Economist, Pearson might well be flogging the wrong assets at the wrong time, says Matthew Lynn.